Patients with residual invasive disease after standard neoadjuvant chemotherapy for HER2-negative breast cancer benefit from adjuvant treatment with capecitabine, CREATE-X trial data show.

Patients with prostate cancer can be classified into luminal- and basal-like subtypes using the well-known PAM50 algorithm, and the subtypes correlate with clinical outcome, researchers report.

The efficacy and safety profiles of disease activity-guided dose reduction of tumor necrosis factor inhibitors are maintained for up to 3 years in patients with rheumatoid arthritis, follow-up results of the DRESS study suggest.

Study findings suggest that bosutinib could be considered as an alternative to imatinib for first-line tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.

The ARCHER 1050 investigators believe that their results establish dacomitinib as an addition to the first-line EGFR mutation-positive non-small-cell lung cancer treatment armamentarium, but caution that the associated toxicity needs to be managed.

Compared with crizotinib, alectinib significantly improves progression-free survival in treatment-naïve patients with advanced non-small-cell lung cancer harboring an anaplastic lymphoma kinase rearrangement, shows the ALEX trial.

medwireNews brings you news and conference reports from the ESMO 2016 Congress, held in Copenhagen, Denmark.

Click through to read the full reports of the latest research.

Visit our dedicated microsite for research news, interviews and in-depth analysis of paediatric endocrinology and growth disorders.

Highlights from the 1st conference of the European Academy of Neurology in Berlin, Germany.

Click through to read research news from the conference.